Denali Therapeutics Inc.
NEWS
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
In a paper published on Wednesday, Denali detailed the engineering of its transport vehicles.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
JOBS
IN THE PRESS